1. Home
  2. GTEC vs SYBX Comparison

GTEC vs SYBX Comparison

Compare GTEC & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenland Technologies Holding Corporation

GTEC

Greenland Technologies Holding Corporation

HOLD

Current Price

$1.06

Market Cap

17.7M

Sector

Industrials

ML Signal

HOLD

Logo Synlogic Inc.

SYBX

Synlogic Inc.

N/A

Current Price

$1.22

Market Cap

15.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GTEC
SYBX
Founded
2006
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.7M
15.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GTEC
SYBX
Price
$1.06
$1.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
463.9K
34.1K
Earning Date
11-07-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.92
N/A
Revenue
$86,168,664.00
N/A
Revenue This Year
$5.64
N/A
Revenue Next Year
$3.93
N/A
P/E Ratio
$0.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.58
$0.90
52 Week High
$2.92
$1.96

Technical Indicators

Market Signals
Indicator
GTEC
SYBX
Relative Strength Index (RSI) 58.42 47.80
Support Level $0.58 $1.17
Resistance Level $1.15 $1.27
Average True Range (ATR) 0.10 0.07
MACD 0.02 0.02
Stochastic Oscillator 80.73 61.11

Price Performance

Historical Comparison
GTEC
SYBX

About GTEC Greenland Technologies Holding Corporation

Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Share on Social Networks: